Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) and Inventiva (NASDAQ:IVA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.
Volatility & Risk
Lexaria Bioscience has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
Profitability
This table compares Lexaria Bioscience and Inventiva’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lexaria Bioscience | -1,685.84% | -206.02% | -162.53% |
| Inventiva | N/A | N/A | N/A |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lexaria Bioscience | $710,000.00 | 20.14 | -$11.90 million | ($0.47) | -1.23 |
| Inventiva | $5.07 million | 165.53 | -$400.67 million | N/A | N/A |
Lexaria Bioscience has higher earnings, but lower revenue than Inventiva.
Analyst Recommendations
This is a breakdown of recent ratings for Lexaria Bioscience and Inventiva, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lexaria Bioscience | 1 | 0 | 1 | 0 | 2.00 |
| Inventiva | 1 | 0 | 6 | 3 | 3.10 |
Lexaria Bioscience presently has a consensus target price of $1.50, indicating a potential upside of 160.06%. Inventiva has a consensus target price of $16.56, indicating a potential upside of 187.92%. Given Inventiva’s stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Lexaria Bioscience.
Insider & Institutional Ownership
13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Inventiva beats Lexaria Bioscience on 12 of the 13 factors compared between the two stocks.
About Lexaria Bioscience
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
